Trial Profile
A Pilot Study of Rapid HIV Treatment Initiation, Access and Engagement in Care (RHAE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2022
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms RHAE
- 07 Oct 2020 Status changed from recruiting to completed.
- 08 May 2020 Planned End Date changed from 13 May 2020 to 13 Sep 2020.
- 08 May 2020 Planned primary completion date changed from 13 May 2020 to 13 Sep 2020.